Sunitinib malate for the treatment of solid tumours: a review of current clinical data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

Published:2006-04-24 Issue:5 Volume:15 Page:553-561
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Motzer Robert J¹,Hoosen Sakina²,Bello Carlo L³,Christensen James G⁴

Affiliation:

1. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

2. Pfizer, Inc., 235 East 42nd Street, New York, NY 10017, USA.

3. Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA.

4. Pfizer Global Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA.

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.15.5.553

Reference56 articles.

1. Tyrosine Kinases as Targets for Cancer Therapy

2. Autoinhibition Control

3. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib

4. RABEN D, HELFRICH B, BUNN PA Jr: Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.Int. J. Radiat. Oncol. Biol. Phys.(2004) 59(Suppl. 2):27-38.

5. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in multitarget-directed ligands via in silico drug discovery;Drug Discovery Today;2024-03

2. The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study;2023-06-26

3. Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition;Drug Research;2023-02-23

4. Protein kinase inhibitors and cancer targeted therapy;Protein Kinase Inhibitors;2022

5. Tumor-Targeting Agents;Nuclear Medicine and Immunology;2021-11-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3